Revefenacin

Revefenacin
Clinical data
Trade names	Yupelri
AHFS/Drugs.com	Monograph
MedlinePlus	a619009
License data	US DailyMed: Revefenacin;
Routes of; administration	Inhalation
ATC code	R03BB08 (WHO) ;
Legal status
Legal status	US: ℞-only;
Identifiers
CAS Number	864750-70-9;
PubChem CID	11753673;
DrugBank	DB11855;
ChemSpider	9928376;
UNII	G2AE2VE07O;
KEGG	D10978;
CompTox Dashboard (EPA)	DTXSID701027775 ;
Chemical and physical data
Formula	C35H43N5O4
Molar mass	597.760 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN(CCN1CCC(CC1)OC(=O)NC2=CC=CC=C2C3=CC=CC=C3)C(=O)C4=CC=C(C=C4)CN5CCC(CC5)C(=O)N;
	InChI InChI=1S/C35H43N5O4/c1-38(34(42)29-13-11-26(12-14-29)25-40-19-15-28(16-20-40)33(36)41)23-24-39-21-17-30(18-22-39)44-35(43)37-32-10-6-5-9-31(32)27-7-3-2-4-8-27/h2-14,28,30H,15-25H2,1H3,(H2,36,41)(H,37,43); Key:FYDWDCIFZSGNBU-UHFFFAOYSA-N;

Revefenacin, sold under the brand name Yupelri, is a medication for the treatment of chronic obstructive pulmonary disease (COPD). It was approved for use in the United States in 2018. It was developed by Theravance Biopharma and is marketed by Mylan. Revefenacin is formulated as a solution that is nebulized and inhaled.

Revefenacin is a bronchodilator that exerts its effect as a long-acting muscarinic antagonist.